Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Cancers·2026
Same author

Follicular Lymphoma: Paving the Path to Cures Through Philanthropy.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.

Oncotarget·2024
Same author

Exploring the Effects of Instruction and Game Design on Youth Soccer Players' Skill Involvement and Cooperative Team Behaviour.

Research quarterly for exercise and sport·2024
Same author

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.

Blood·2024
Same author

Understanding the role of gaze behaviour and coaching experience in the assessment of youth soccer teams.

Science & medicine in football·2024

Related Experiment Video

Updated: Apr 7, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K

Ibrutinib in B lymphoid malignancies.

Mitchell R Smith1

  • 1Taussig Cancer Institute, Cleveland Clinic , 9500 Euclid Avenue, Cleveland, OH , USA +1 216 444 4366 ; +1 216 444 9464 ; smithm14@ccf.org.

Expert Opinion on Pharmacotherapy
|July 14, 2015
PubMed
Summary

Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, shows significant efficacy and tolerability in treating B cell leukemias and lymphomas. This targeted therapy is transforming treatment approaches for these challenging hematologic malignancies.

Keywords:
B cell receptorbruton’s tyrosine kinasechronic lymphocytic leukemianon-Hodgkin lymphoma

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K

Related Experiment Videos

Last Updated: Apr 7, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Most B cell lymphomas and lymphoid leukemias are currently incurable with standard therapies.
  • Survival of B cells relies on B-cell receptor signaling, with Bruton's tyrosine kinase (BTK) being a key component.
  • Ibrutinib, an oral BTK inhibitor, is FDA-approved for multiple indications, demonstrating substantial benefit in indolent B cell malignancies.

Purpose of the Study:

  • To review the clinical pharmacology of ibrutinib.
  • To summarize the efficacy of ibrutinib in clinical trials for specific B cell disorders.
  • To discuss the safety, toxicity, and future directions of ibrutinib treatment.

Main Methods:

  • Literature review of clinical pharmacology.
  • Analysis of efficacy data from clinical trials.
  • Assessment of safety and toxicity profiles.

Main Results:

  • Ibrutinib is a well-tolerated, once-daily oral medication.
  • Demonstrates impressive activity as a single agent in indolent B cell lymphoproliferative disorders.
  • Already impacting treatment paradigms in approved indications.

Conclusions:

  • Ibrutinib is a valuable therapeutic option for indolent B cell lymphoproliferative disorders.
  • Ongoing research is evaluating its use in front-line settings and combination therapies.
  • Further studies will define its role in a broader range of B cell malignancies.